Equities

Fusen Pharmaceutical Co Ltd

Fusen Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)0.98
  • Today's Change-0.07 / -6.67%
  • Shares traded20.00k
  • 1 Year change-30.00%
  • Beta0.1648
Data delayed at least 15 minutes, as of Jul 19 2024 04:48 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fusen Pharmaceutical Co Ltd is a company mainly engaged in the cultivation of Chinese herbal medicine, pharmaceutical research and development, and sales. The Company's main business is the sales of Shuanghuanglian Oral Solutions, Shuanghuanglian Injections and other pharmaceutical products. The Company is also engaged in the research, production, and sales of various proprietary Chinese medicine and western medicine products for treating cold, fever, cardiovascular diseases and anemia. The Company mainly conducts business in the domestic market.

  • Revenue in HKD (TTM)607.56m
  • Net income in HKD-38.97m
  • Incorporated2013
  • Employees1.15k
  • Location
    Fusen Pharmaceutical Co LtdUrban Industrial Zone, Xichuan CountyNANYANG ChinaCHN
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Wai Yuen Tong Medicine Holdings Limited783.88m-26.68m393.79m1.96k--0.29554.810.5024-0.0228-0.01320.66361.180.17210.400110.55---0.1597-0.3053-0.2538-0.520650.3743.82-0.928-2.181.371.240.2497--8.330.8488-62.16------
Tianda Pharmaceuticals Ltd532.09m-24.16m569.76m863.00--0.962349.971.07-0.0112-0.01120.24750.27540.53064.884.37616,557.40-2.49---3.84--48.02---4.70--0.8907-13.980.161--------------
Transcenta Holding Limited57.84m-496.88m619.32m215.00--0.5599--10.71-1.22-1.220.14212.540.02812.051.49269,037.00-24.17---33.97--26.74---859.01--1.20-32.870.285---47.15---13.72------
Lee's Pharmaceutical Holdings Ltd1.05bn16.70m671.27m1.06k40.200.32924.300.63750.02840.02841.793.460.37131.8310.75996,247.900.703313.330.8817.7652.3561.921.8936.200.55263.900.09433.59-14.61-1.53-67.44-47.49-12.19-31.34
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd903.96m159.20m728.33m848.004.570.4585.970.80570.28420.28421.612.840.35872.182.941,065,993.006.327.679.1210.4869.4078.7917.6120.681.51--0.05157.22-0.00495.38-23.43-1.67-1.14--
Pak Fah Yeow International Ltd259.16m105.04m747.94m102.007.120.97756.652.890.3370.3370.83162.460.29952.8822.182,540,765.0012.143.9912.604.1884.4580.7940.5321.276.9010.080.0062100.6876.0612.94250.6623.0218.83-8.06
Fusen Pharmaceutical Co Ltd607.56m-38.97m757.46m1.15k--1.25--1.25-0.0522-0.05220.80790.80710.41991.958.36529,232.40-2.690.9678-5.541.7452.9551.95-6.422.590.60960.7560.379727.9515.024.13-4.83--0.2124--
Zhaoke Ophthalmology Ltd20.14m-413.60m770.06m313.00--0.35--38.23-0.7604-0.76040.0374.030.0075--0.53164,347.21-15.43---17.27--75.98---2,053.54--5.32-47.540.1041------5.47------
Jbm (Healthcare) Ltd648.42m130.46m825.47m279.006.690.84784.491.270.14790.14790.73381.170.46454.255.982,324,068.009.834.3812.045.5252.1446.4721.1612.691.2589.680.115532.9824.6216.09128.5119.992.26--
Zhongzhi Pharmaceutical Holdings Ltd2.20bn174.85m993.14m2.64k5.570.88183.470.4510.20640.20642.601.301.122.5310.54833,085.608.957.6914.1511.7559.7360.448.016.730.894--0.142442.4612.2612.4153.0013.8617.653.22
Ascletis Pharma Inc60.79m-155.45m1.05bn219.00--0.431--17.33-0.1461-0.14610.05662.410.0222.303.86277,596.80-5.62-6.43-5.91-6.6445.9235.67-255.70-243.3816.54-6.090.0036--4.63-19.3954.04---20.44--
VIVA Biotech Holdings2.32bn-124.73m1.08bn2.08k--0.27039.030.4667-0.0634-0.06341.191.850.28054.845.211,114,808.00-1.30-1.39-1.79-1.6834.2634.81-4.63-5.441.151.000.3412---9.4259.3178.03--31.98--
Hbm Holdings Ltd698.80m177.99m1.13bn177.006.071.155.281.620.24210.24210.95211.280.38863.903.013,947,999.009.88-54.6114.13-66.0497.7397.8125.43-400.283.286.980.3556--120.13127.06116.61---12.62--
Data as of Jul 19 2024. Currency figures normalised to Fusen Pharmaceutical Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.03%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 30 Apr 2024196.00k0.03%
Dimensional Fund Advisors Ltd.as of 31 May 202414.45k0.00%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.